Search Results | Diabetes | American Diabetes Association

1-15 of 15

Sort by

Sort Order Select

Meeting Abstracts

1230-P: Patient-Reported Outcomes (PROs) to Treatment in Type 2 Diabetes (T2D) from the International Diabetes Management Practices Study (IDMPS)

PABLO ASCHNER, JUAN J. GAGLIARDINO, HASAN M. ILKOVA, AMBADY RAMACHANDRAN, JEAN CLAUDE MBANYA, MARINA V. SHESTAKOVA, VALERIE PILORGET, LYDIE MELAS-MELT, JEAN-MARC CHANTELOT, JULIANA C. CHAN

Diabetes 2022;71(Supplement_1):1230-P

DOI: https://doi.org/10.2337/db22-1230-P

Published: 01 June 2022

View article

Meeting Abstracts

814-P: Treatment Satisfaction in People with T2D Switched from Basal Insulin (BI) to Insulin Glargine 300 U/mL (Gla-300) : Patient-Reported Outcomes from ARTEMIS-DM Study

KHALID ALRUBEAAN, EMMA G. WILMOT, AUDE ROBOREL DE CLIMENS, MARIA AILEEN N. MABUNAY, VALERIE PILORGET, BAPTISTE BERTHOU, GUSTAVO FRECHTEL, BIPIN SETHI

Diabetes 2022;71(Supplement_1):814-P

DOI: https://doi.org/10.2337/db22-814-P

Published: 01 June 2022

View article

Meeting Abstracts

813-P: Treatment Satisfaction and Health Status in People with T2D Treated with Insulin Glargine 300 U/mL (Gla-300) : Patient-Reported Outcomes (PRO) from ATOS Study

NIAZ KHAN, AMIR TIROSH, ANIL BHANSALI, HERNANDO VARGAS-URICOECHEA, STEWART B. HARRIS, AUDE ROBOREL DE CLIMENS, MARIA AILEEN N. MABUNAY, MATHIEU COUDERT, VALERIE PILORGET, GAGIK R. GALSTYAN

Diabetes 2022;71(Supplement_1):813-P

DOI: https://doi.org/10.2337/db22-813-P

Published: 01 June 2022

View article

Meeting Abstracts

105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial

RICHARD M. BERGENSTAL, STEVEN EDELMAN, PRATIK CHOUDHARY, THOMAS DANNE, ERIC RENARD, JUKKA WESTERBACKA, BHASWATI MUKHERJEE, PASCALINE PICARD, VALERIE PILORGET, TADEJ BATTELINO

Diabetes 2022;71(Supplement_1):105-LB

DOI: https://doi.org/10.2337/db22-105-LB

Published: 01 June 2022

View article

Meeting Abstracts

184-LB: Patient-Reported Outcomes (PROs) to Treatment in Type 1 Diabetes (T1D) from the International Diabetes Management Practices Study (IDMPS)

JUAN J. GAGLIARDINO, PABLO ASCHNER, HASAN M. ILKOVA, AMBADY RAMACHANDRAN, JEAN CLAUDE MBANYA, MARINA V. SHESTAKOVA, VALERIE PILORGET, LYDIE MELAS-MELT, JEAN-MARC CHANTELOT, JULIANA C. CHAN

Diabetes 2022;71(Supplement_1):184-LB

DOI: https://doi.org/10.2337/db22-184-LB

Published: 01 June 2022

View article

Meeting Abstracts

745-P: Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM): ATOS Study Subgroup Analysis by Baseline (BL) HbA1c

NIAZ KHAN, AMIR TIROSH, HERNANDO VARGAS-URICOECHEA, MARIA AILEEN N. MABUNAY, MATHIEU COUDERT, VALERIE PILORGET, GAGIK R. GALSTYAN

Diabetes 2021;70(Supplement_1):745-P

DOI: https://doi.org/10.2337/db21-745-P

Published: 01 June 2021

View article

Meeting Abstracts

743-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM) and Renal Impairment (RI): A Subgroup Analysis of the ATOS Study

AMIR TIROSH, NIAZ KHAN, HERNANDO VARGAS-URICOECHEA, MARIA AILEEN N. MABUNAY, MATHIEU COUDERT, VALERIE PILORGET, GAGIK R. GALSTYAN

Diabetes 2021;70(Supplement_1):743-P

DOI: https://doi.org/10.2337/db21-743-P

Published: 01 June 2021

View article

Meeting Abstracts

737-P: Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes Mellitus (T2DM) Uncontrolled on Basal Insulins (BI): ARTEMIS-DM Study

BIPIN SETHI, KHALID ALRUBEAAN, MUSTAFA UNUBOL, MARIA AILEEN N. MABUNAY, MUBARAK NAQVI, BAPTISTE BERTHOU, VALERIE PILORGET, GUSTAVO FRECHTEL

Diabetes 2021;70(Supplement_1):737-P

DOI: https://doi.org/10.2337/db21-737-P

Published: 01 June 2021

View article

Meeting Abstracts

194-OR: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Older Adults (≥70 Years) with Type 2 Diabetes (T2DM): A Subgroup Analysis of the ATOS Study

GAGIK R. GALSTYAN, AMIR TIROSH, HERNANDO VARGAS-URICOECHEA, MARIA AILEEN N. MABUNAY, MATHIEU COUDERT, VALERIE PILORGET, NIAZ KHAN

Diabetes 2021;70(Supplement_1):194-OR

DOI: https://doi.org/10.2337/db21-194-OR

Published: 01 June 2021

View article

Meeting Abstracts

1028-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naïve Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study

GAGIK R. GALSTYAN, ANIL BHANSALI, HERNANDO VARGAS-URICOECHEA, AMIR TIROSH, GUANNAN SUN, MUBARAK NAQVI, VALERIE PILORGET, MATHIEU COUDERT, DMITRY CHERKASOV, NIAZ KHAN

Diabetes 2020;69(Supplement_1):1028-P

DOI: https://doi.org/10.2337/db20-1028-P

Published: 01 June 2020

View article

Meeting Abstracts

1035-P: Real-World Safety and Effectiveness of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes (T2DM) Who Fast during Ramadan: Regional Analysis of the ORION Study

MOHAMED HASSANEIN, MEHMET A. BUYUKBESE, RACHID MALEK, SR., VALERIE PILORGET, MUBARAK NAQVI, BAPTISTE BERTHOU, INASS SHALTOUT, RAKESH SAHAY

Diabetes 2020;69(Supplement_1):1035-P

DOI: https://doi.org/10.2337/db20-1035-P

Published: 01 June 2020

View article

Meeting Abstracts

1626-P: Differences in Patient-Reported Outcomes (PROs) by Age and Region in Adults with Type 1 Diabetes (T1D) in the SAGE Study

LORI BERARD, FRANCISCO JAVIER AMPUDIA BLASCO, SANDRINE BRETTE, DANIELA BRUTTOMESSO, KELLY L. CLOSE, HIROSHI IKEGAMI, DUBRAVKA JURIŠIC-ERŽEN, FELIPE LAUAND, SR., ANNE L. PETERS, VALERIE PILORGET, RAMANATHAN BALAMURUGAN, ERIC RENARD, EMMA G. WILMOT, AUDE ROBOREL DE CLIMENS

Diabetes 2020;69(Supplement_1):1626-P

DOI: https://doi.org/10.2337/db20-1626-P

Published: 01 June 2020

View article

Meeting Abstracts

1625-P: Association of Patient- and Disease-Related Factors with Glycemic Target Achievement in Type 1 Diabetes (T1D) in the SAGE Study

JOCHEN SEUFERT, HIROSHI IKEGAMI, SANDRINE BRETTE, VALERIE PILORGET, FELIPE LAUAND, SR., EMMA G. WILMOT, ERIC RENARD, JUAN J. GAGLIARDINO

Diabetes 2020;69(Supplement_1):1625-P

DOI: https://doi.org/10.2337/db20-1625-P

Published: 01 June 2020

View article

Meeting Abstracts

Achievement of Individualized HbA1c Targets with Self- vs. Physician-Led Titration of Basal Insulin (BI) in People with Type 2 Diabetes (T2DM), Newly or Recently Initiated on BI—Results from the DUNE Real-World Study

LORI BERARD, DIDAC MAURICIO, KAMLESH KHUNTI, DENISE R. FRANCO, JUKKA WESTERBACKA, CHRISTOPHE CANDELAS, VALERIE PILORGET, RICCARDO PERFETTI, LUIGI MENEGHINI

Diabetes 2018;67(Supplement_1):1039-P

DOI: https://doi.org/10.2337/db18-1039-P

Published: 01 July 2018

View article

Meeting Abstracts

Change in Insulin Dose and HbA1c by Geographical Region—Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study

DIDAC MAURICIO, LUIGI MENEGHINI, EMANUELA ORSI, VADIM KLIMONTOV, JUKKA WESTERBACKA, LYDIE MELAS-MELT, VALERIE PILORGET, RICCARDO PERFETTI, KAMLESH KHUNTI

Diabetes 2018;67(Supplement_1):1037-P

DOI: https://doi.org/10.2337/db18-1037-P

Published: 01 July 2018

View article

NARROW

1230-P: Patient-Reported Outcomes (PROs) to Treatment in Type 2 Diabetes (T2D) from the International Diabetes Management Practices Study (IDMPS)

814-P: Treatment Satisfaction in People with T2D Switched from Basal Insulin (BI) to Insulin Glargine 300 U/mL (Gla-300) : Patient-Reported Outcomes from ARTEMIS-DM Study

813-P: Treatment Satisfaction and Health Status in People with T2D Treated with Insulin Glargine 300 U/mL (Gla-300) : Patient-Reported Outcomes (PRO) from ATOS Study

105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial

184-LB: Patient-Reported Outcomes (PROs) to Treatment in Type 1 Diabetes (T1D) from the International Diabetes Management Practices Study (IDMPS)

745-P: Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM): ATOS Study Subgroup Analysis by Baseline (BL) HbA1c

743-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM) and Renal Impairment (RI): A Subgroup Analysis of the ATOS Study

737-P: Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes Mellitus (T2DM) Uncontrolled on Basal Insulins (BI): ARTEMIS-DM Study

194-OR: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Older Adults (≥70 Years) with Type 2 Diabetes (T2DM): A Subgroup Analysis of the ATOS Study

1028-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naïve Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study

1035-P: Real-World Safety and Effectiveness of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes (T2DM) Who Fast during Ramadan: Regional Analysis of the ORION Study

1626-P: Differences in Patient-Reported Outcomes (PROs) by Age and Region in Adults with Type 1 Diabetes (T1D) in the SAGE Study

1625-P: Association of Patient- and Disease-Related Factors with Glycemic Target Achievement in Type 1 Diabetes (T1D) in the SAGE Study

Achievement of Individualized HbA1c Targets with Self- vs. Physician-Led Titration of Basal Insulin (BI) in People with Type 2 Diabetes (T2DM), Newly or Recently Initiated on BI—Results from the DUNE Real-World Study

Change in Insulin Dose and HbA1c by Geographical Region—Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only